GlassScriptPhysician profile
Matthew Wilcox
NPI 1528645785
$2,013.97
in general payments reported to CMS, 2019-2025
26 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $487 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,013.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $262.16 | 2024-2025 | |
| Novo Nordisk INC | $224.46 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $197.95 | 2024-2025 | Caplyta |
| Abbvie INC. | $192.91 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $164.31 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Exact Sciences Corporation | $134.02 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $119.28 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $94.77 | 2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Axsome Therapeutics, INC. | $82.60 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $80.19 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.84 | 2024-2025 | Xifaxan |
| Astellas Pharma US INC | $56.75 | 2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $51.56 | 2024-2025 | Voquezna |
| Dexcom, INC. | $48.91 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $34.91 | 2025 | Repatha, Otezla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23.02 | 2024 | Endo Gia Ultra |
| Takeda Pharmaceuticals U.S.A., INC. | $21.63 | 2024 | Trintellix |
| Seqirus USA INC | $19.54 | 2024 | Fluad, Flucelvax |
| Ethicon US, LLC | $18.76 | 2024 | Dermabond |
| Corcept Therapeutics | $18.68 | 2024 | Korlym |
| Esperion Therapeutics, INC. | $18.44 | 2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $15.86 | 2025 | Eliquis |
| Lundbeck LLC | $15.29 | 2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $14.79 | 2025 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.85 | 2025 | Jardiance |
| Sumitomo Pharma America, INC. | $13.49 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Wilcox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.